Abstract: A method of inducing autophagy in a cell is achieved by contacting the cell with graphene oxide (GO) in an amount effective to induce autophagy in the cell, wherein the cell expresses at least one of TLR-4 (Toll-like receptor 4) and TLR-9 (Toll-like receptor 9). Differences between autophagy triggered by GO and other conventional agonists such as rapamycin have been observed. GO may activate autophagy in some cells that may not be triggered by rapamycin. The cell reveals no apparent apoptosis after treatment of the graphene oxide. A method of method of potentiating an antitumor immune response is also herein provided.

Abstract: A solution for electrolyte replacement, suitable for parenteral administration and pediatric use, particularly useful in hospital contexts for maintaining the hydro-electrolyte balance, in particular for preventing iatrogenic hyponatremia, which allows to provide a proper potassium and sodium supply for the electrolyte replacement, and at the same time, it retains proper glucose levels, without inducing acidosis is disclosed.

Abstract: The present disclosure generally relates to the medical use of compositions comprising a mineral salt and a sulfonic acid for prevention and/or treatment of one or more mucosal diseases, disorders, or conditions or one or more dermal diseases, disorders, or conditions.

Abstract: Current technologies to treat end stage renal disease (ESRD) include peritoneal dialysis, hemodialysis and transplantation all of which are expensive. This invention is an inexpensive method to decrease body toxins that requires immersion of a body in a hot water bath with sorbents. In a hot water bath, secretory coils within activated sweat glands function as a semipermeable membrane that can dialyze toxins. Sorbents such charcoals and smectite clays located within the secretory coils of sweat glands in the vicinity of the zonula occludens can adsorb toxins. A subject who was immersed in a hot water bath with dissolved activated charcoal for a total time of approximately two hours presumably developed heparin deficiency from the adsorption of heparin onto activated charcoal.

Abstract: The present invention relates to hepatocyte-like cells. Also disclosed are methods of making the cells and using the cells.

Abstract: The invention relates to of analyzing vector supernatants useful for transducing T cells destined for administration to a human subject. The invention also related to methods of analyzing transduced T cells destined for administration to a human subject.

Abstract: The present invention relates to the use of exosome-preparations derived from neonatal or adult tissue-derived mesenchymal stem-cells (MSCs) for the prevention or for therapy of inflammatory conditions, such as, for example, pre- and postnatally acquired damages of the brain (i.e. neuronal damages) or in complications following stem cell transplantation (“graft vs host-disease”, GvHD).

Abstract: We describe a particle secreted by a mesenchymal stem cell and comprising at least one biological property of a mesenchymal stem cell. The biological property may comprise a biological activity of a mesenchymal stem cell conditioned medium (MSC-CM) such as cardioprotection or reduction of infarct size. The particle may comprise a vesicle or an exosome.

Abstract: The invention relates to a method for isolating muscle-derived stem cells that can be used in cell therapy, said method comprising the steps of (i) dissociating cells from at least one muscle sample, (ii) plating the cells obtained at the end of step (i) on a non-coated cell container, (iii) isolating the cells present in the supernatant of the non-coated cell container obtained at the end of step (ii), (iv) plating the cells obtained at the end of step (iii) on a coated cell container, (v) isolating the cells present in the supernatant of the coated cell container obtained at the end of step (iv), (vi) repeating, or not, the steps (iii) and (iv) at least one or two times, (vii) plating and culturing the cells isolated from the supernatant of the coated cell container obtained at the end of step (vi) until said cells have reached a confluence level of at least 50%, (viii) isolating, at the end of step (vii), the stem cells which can be used in cell therapy, wherein after expansion (a) at least 95% of said cel

Abstract: Embodiments of the invention stimulate three levels of beta cell physiology: (i) glucose metabolism, (ii) membrane receptor function, and (iii) transcriptional factors that result in the in vivo formation of beta cells in the pancreas for the purpose of treating diabetes. In certain aspects, the methods include the integration of three levels of cellular physiology: metabolism, membrane receptor function, and gene transcription. The integration of multiple levels of cellular physiology produces a synergistic effect on beta cell formation.

Abstract: Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.

Abstract: Provided herein are methods of producing enhanced placental stem cells by modulatory RNA molecules. Also provided herein are methods of using enhanced placental stem cells, for example, to treat individuals having a disease, disorder or condition caused by, or relating to, an unwanted or harmful immune response. Further provided herein are compositions comprising said enhanced placental stem cells.

Abstract: Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.

Abstract: TRFs useful for identifying strains of interest are provided. A method of identifying one or more strain that can be used as a direct-fed microbial is also provided. One or more strain identified by the method is additionally provided. A method is also provided for administering to an animal an effective amount of the one or more strain. Additionally provided is an isolated strain chosen from at least one of Lactobacillus acidophilus strain P1B c6 (NRRL B-50103), Lactobacillus salivarius strain o246e 33w (NRRL B-50102), Pediococcus acidilactici strain o246e 42 (NRRL B-50171), and Pediococcus acidilactici strain P1J e3 (NRRL B-50101). An isolated strain having all of the identifying characteristics of one of the strains listed above is also provided. One or more strain can be administered as a direct-fed microbial to an animal. Methods of preparing a direct-fed microbial are also provided.

Abstract: According to the present invention there are provided methods of use in companion animals of probiotic bacteria of the genus Bifidobacteria.

Abstract: The disclosure relates to an isolated strain of Lactobacillus crispatus, identified as IP174178 and deposited at the CNCM under number 1-464 or an isolated strain having the same characteristics as IP174178. The disclosure also relates to a pharmaceutical composition or a nutraceutical composition including such a strain, and to the use thereof for the treatment or prevention of genital infections.

Abstract: The disclosure relates to a solid glass matrix of polysaccharide, saccharides and polyols as delivery vehicles for preservation and post gastric administration of a probiotic. The delivery vehicle is capable of releasing the probiotic at their site of action. The present invention further includes methods of making and using the solid glass matrix delivery vehicle of the invention.

Abstract: The present invention relates to a blood pressure reducing composition and primers for Monascus purpureus NTU 568, wherein the composition is a red mold dioscorea (RMD) manufacturing by way of inoculating a Monascus purpureus NTU 568 to a dioscorea substrate and then treating the inoculated dioscorea with culturing and drying processes. This composition is able to reduce blood pressure and prevent the vascular wall from pathological deterioration; therefore, the composition can be applied to clinical treatment and health food. Moreover, at least one nucleotide sequence for M. purpureus NTU 568 and the primers for the nucleotide sequence are also provided in the present invention in order to facilitate the person skilled in Monascus purpureus related art capable of accomplishing the strain (mutant) identification of the M. purpureus NTU 568.

Abstract: An extract of Asplenium nidus L. includes pyropheophorbide a methyl ester (C34H36N4O3), pheophorbide a methyl ester (C35H36N4O5), 1-linleoyl-3-linolenoyl-glycerol (C39H66O5), 1-linleoyl-2,3-dipalmitoyl-rac-glycerol (C53H98O6) and 1,3-dipalmitoyl-sn-glycerol (C35H68O5). The extract of Asplenium nidus L. is obtained by using a method including steps of: solvent extraction, using an solvent to extract an Asplenium nidus L. sample and to obtain an extract, with a w/v ratio between the solvent and the Asplenium nidus L. sample being 50˜60 mg/ml; and column chromatography, fractionating the extract with water and ethanol as eluent to obtain several fractions including fraction a to fraction i, and further evaporating and lyophilizing fraction b, c, d or their combination to obtain an extract of Asplenium nidus L.

Abstract: A method for modifying THC content in a lipid-based extract of cannabis to yield a low-THC product. The method includes providing a lipid-based extract of cannabis containing THC, heating the lipid-based extract at 1 atm of pressure to 157 to 160° C. to vaporize a first portion of the THC, and converting a second portion of the THC to CBN by heating the lipid-based extract to between 130° C.-150° C. for at least 10 min.

Abstract: A nutritional supplement is provided containing two broccoli based components that are combined and, when ingested, react in the intestines to provide sulforaphane. Processes for producing the broccoli components of the nutritional supplement are also provided. The broccoli components are treated separately using supercritical fluid extraction to remove oils. The temperature and pressure of the supercritical extraction processes are controlled to provide broccoli components having the desired properties for the nutritional supplement.

Abstract: The invention relates to a novel use of the Chinese herb Glycyrrhiza inflata in treatment of neurodegenerative disorders. Particularly, the invention relates to the use of ammonium glycyrrhizinate and licochalcone A in targeting polyQ-mediated spinocerebellar ataxia.

Abstract: The present invention is directed to methods for extracting and isolating extracts having angiogenesis inhibiting activity from a latex-containing portion of a Ficus variant, pharmaceutical and nutraceutical compositions comprising the extracts, methods of administering the extracts to treat angiogenesis-dependent diseases and to reduce or inhibit neovessel growth in a subject in need thereof and the use of the extracts in the manufacture of a composition for reducing or inhibiting neovessel growth.

Abstract: The present invention provides a method for treating type II diabetes, conditions associated therewith, or both, by administering to a subject in need thereof a therapeutically effective amount of a herbal composition comprising (i) an extract of leaves of at least one Morus species, (ii) at least one Urtica species or an extract thereof, and (iii) at least one Artemisia species or an extract thereof.

Abstract: The invention relates to a dermatological composition containing a myrtle extract in a concentration that is higher than or equal to 0.01 wt.%, for the use thereof as an anti-biofilm agent against Propionibacterium acnes.

Abstract: A primary object of the invention is to provide a composition for the prevention, amelioration, or treatment of metabolic syndrome and to provide a food or drink, a medicine, or a feed comprising the composition. A composition for the prevention, amelioration, or treatment of metabolic syndrome, the composition comprising the following (a) and (b): (a) a rose hip extract, and (b) at least a kind of xanthine derivatives.

Abstract: Methods of treating drug side-effects including gastrointestinal spasms are provided, such methods not requiring the use of systemic drugs that have shown to (i) provide slow relief, (ii) cause adverse side effects, (iii) limit activities, (iv) worsen existing gastrointestinal conditions, (v) be unrecommended in several gastrointestinal conditions that include gastrointestinal spasms, or (vi) be unrecommended in the absence of diarrhea.

Abstract: Ingredient for consumption and application is created in various methods and forms so that the ingredient is available for the consumer in a convenient, effective, and efficient manner. The ingredient includes plant ingredient, chinese medicine, nutritional ingredient, health ingredient, cleansing ingredient, and food additive. Ingredient for consumption and application comprising at least one ingredient. The ingredient having nutrients including carbohydrates, vitamins, minerals, and antioxidants; having medicinal properties; and having cleansing properties. The ingredient is in form selected from group consisting of skin, skinned, unskinned, unshelled, cut, uncut, extract, juice, sauce, liquid, oil, gel, jelly, wax, cream, paste, powder, thin layer, small particles, small and large pieces. The ingredient can be uncooked; and cooked by method selected from group consisting of deep frying, sun drying, roasting, baking, steaming, boiling, grilling, and frying.

Abstract: A composition and a method for treating hyperlipidemia caused by excessive consumption of lamb. The composition comprises in various parts: root of anhwei barberry, folium isatidis, garden erphorbia herb, aster ageratoides, Vietnamese sophora root, codonopsis ianceolata, all-grass of snakefoot clubmoss, apanese stephania root, amur barberry root, thymifoious euphorbia herb, puff-ball, meadowrue root and rhizome, cottonrose hibiscus flower, common lantana leaf, herba orostachyos, Japanese dock root, pubescent holly root, Chinese brake herb, fruit of tree-of-heaven ailanthus, Chinese iris seed, European verbena herb, datura seed, wild buckwheat rhizome, filliform cassytha herb, fig, radix cynanchi atrati, bittersweet herb, Chinese pulsatilla root, spreading hedyotis herb, figwort root, herb of hygrometric boea, radix ardisiae crenatae, sowthistle tasselflower herb, weeping forsythia, roughhaired holly root, tree peony bark, membrane of chicken gizzard, carrot, medicated leaven, and radix glycyrrhizae.

Abstract: The present invention relates to a pharmaceutical composition containing Kaempferia parviflora Wall. Ex. Baker extracts for treating muscle diseases, and more specifically to a pharmaceutical composition containing, as an active ingredient, Kaempferia parviflora Wall. Ex. Baker extracts or flavone compound isolated therefrom for treating muscle diseases or a dietary composition for improving muscle function. Kaempferia parviflora Wall. Ex. Baker extracts or flavone compound isolated therefrom according to the present invention reduces protein catabolism in the muscles and increases muscle cell differentiation and anabolism, and is thus effective for preparing pharmaceutical composition for treating muscle diseases and dietary composition for improving muscle function.

Abstract: A composition and a method for treating hyperlipidemia caused by excessive consumption of alcohol. The composition comprises in various parts: folium mahoniae, tender catchweed bedstraw herb, common dysosmatis rhizome and root, root of anhwei barberry, folium isatidis, garden erphorbia herb, dogtooth violet, climbing groundsel herb, huperzia serrata, puff-ball, meadowrue root and rhizome, herba portulacae, Chinese iris seed, European verbena herb, wild buckwheat rhizome, filliform cassytha herb, fig, shrubalthea bark, cottonrose hibiscus flower, cortex fraxini, Japanese white birch bark, peel of bottle gourd, corm of waternut, plumula nelumbinis, watershield, spica prunellae, herba commelinae, copperleaf herb, herba centellae, rhizoma bistortae, fructus gardeniae, radix scutellariae, rhizoma coptidis, cortex phellodendri, tea leaves, herb of spanishneedles, and radix glycyrrhizae.

Abstract: A composition and a method for treating Qi stagnancy and blood stasis type of hyperlipidemia. The composition comprises in various parts: akebia fruit, curcuma root, pomelo, fructus aurantii, fructus aurantii immaturus, star anise, murraya paniculata, aspongopus, sword beans, caesalpinia decapetala, China fir, finger citron, rose, green tangerine peel, sundew, trifoliate orange, kaki calyx, litchi, litchi nucleus, magnolia, cyperus rotundus, citron fruit, Chinese buckeye seed, salvia multiorrhiza, polygonum orientale, motherowrt fruit, euonymus alatus, campsis grandiflora, rhizome of Sichuan lovage, medical cyathula root, vaccaria, Chinese rose flower, balsamine, safflower, azaleas, semen brassicae campestris, caesalpinia sappan, gleditsia spine, myrrh, caulis spatholobi, frankincense, herba lycopi, selaginella, tanarius major, peach seed, and licorice.

Abstract: Various human diseases, including herpes, antibiotic resistant bacterial infections, cutaneous Leishmaniasis, malaria, Ebola and multiple sclerosis can be treated with injections of ginger juice. The ginger juice is produced by cutting, crushing, or otherwise damaging garlic cloves, and collecting the juice. This ginger juice is dissolved in a carrier solution, such as water or saline, and then injected into the patient.

Abstract: The present invention provides methods for using the level of caspase 3 activity for determining or prognosticating likelihood of cancer recurrence or relapse in a patient after the treatment for cancer. The present invention also provides methods for treating cancer in a patient using a caspase 3 inhibitor in conjunction with a conventional cancer treatment.

Abstract: The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as complement pathway modulators for the treatment of ocular diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Abstract: Described are various methods for stabilizing pharmaceutical formulations of a specific Hepatitis C Viral (HCV) inhibitor against the formation of a particular genotoxic degradation product. Such methods include temperature control, moisture control, excipient control, capsule shell control, basification and a reconstitution approach.

Abstract: A method of inhibiting the binding between N-methyl-D-aspartate receptors and neuronal proteins in a neuron is disclosed. The method comprises administering to the neuron an effective inhibiting amount of a peptide replacement agent for the NMDA receptor or neuronal protein interaction domain that effect said inhibition of the NMDA receptor-neuronal protein interaction. The method is of value in reducing the damaging effect of injury to mammalian cells. Postsynaptic density-95 protein (PSD-95) couples neuronal N-methyl-D-aspartate receptors (NMDARs) to pathways mediating excitotoxicity, ischemic and traumatic brain damage. This coupling was disrupted by transducing neurons with peptides that bind to modular domains on either side of the PSD-95NMDAR interaction complex.

Abstract: The present invention relates to isolated, pharmaceutically active, osteopontin-related molecules, pharmaceutical compositions and nutritional supplements comprising such molecules, and use of such compositions and supplements for treating or preventing tumor-generating cancer.

Abstract: The invention relates to an endotoxin-binding lipopeptide selected from the group consisting of polymyxins, polymyxin derivatives, polymyxin analogues, prodrugs thereof and pharmaceutically acceptable salts thereof, and also relates to a preparation for parenteral administration comprising a lipopeptide of this type, for prophylaxis or for treatment of diseases and conditions caused by endotoxemia, by i) parenterally administering a bolus of the lipopeptide to achieve a lipopeptide serum concentration of 0.01 ?g/ml to 0.8 ?g/ml and ii) maintaining this lipopeptide serum concentration by parenterally administering the lipopeptide over a specifiable period of time.

Abstract: The present invention relates to the use of a polypeptides, comprising repeats of a peptide derived from a Heparan Sulphate Proteoglycan (HSPG) receptor binding region of an apolipoprotein, for treating or preventing a fungal and/or protist infection. The invention further relates to the use of such peptides for treating or preventing the contamination of surfaces or objects with such peptides.

Abstract: A method for treatment of a subject having an inflammatory disease of the epithelium comprising the step of administering an amount of a composition comprising an isolated bacterial amyloid peptide to said subject. In embodiments, the composition is membrane-free. In embodiments, the composition comprises a curli fibril. In yet further embodiments, the isolated bacterial amyloid peptide is a CsgA polypeptide, a CsgA polypeptide fragment, a CsgB polypeptide or a CsgB polypeptide fragment. Also provided is a method for decreasing epithelium permeability in a tissue of a subject comprising epithelium comprising the step of administering an amount of a composition comprising an isolated bacterial amyloid peptide to the epithelium of the subject. In embodiments, the composition is membrane-free. In further embodiments, the composition comprises a curli fibril.

Abstract: The present invention relates to a process of producing a composition comprising at least two different proteins, of which at least one is a coagulating protein and at least one is an anti-coagulating protein, comprising the steps of: a) heat-sterilising a first liquid component comprising said coagulating protein, b) heat-sterilising a second liquid component comprising said anti-coagulating protein, and c) mixing said first component with said second component to obtain a mixture thereof. The obtained mixture is useful as a food constituent having reduced coagulation in the upper gastro-intestinal tract, more in particular in the stomach.

Abstract: This invention concerns a HIP/PAP protein or derivative thereof, for its use in treating or managing cancer and preferentially solid tumors.

Abstract: The invention provides methods for treating metabolic disease in a subject and methods for increasing the expression of ILDR2 in a subject. The invention further provides a method for identifying an agent which modulates expression of an Ildr2 RNA comprising contacting a cell with an agent; determining expression of the Ildr2 RNA in the presence and the absence of the agent; and comparing expression of the Ildr2 RNA in the presence and the absence of the agent, wherein a change in the expression of the Ildr2 RNA in the presence of the agent is indicative of an agent which modulates the level of expression of the RNA.

Abstract: The present disclosure relates to the use of RET, a transmembrane tyrosine kinase receptor, agonist molecules for Haematopoietic Stem Cell (HSC) expansion protocols and HSC transplantation therapy. RET signaling molecules are expressed by HSCs and Ret ablation leads to reduced HSC numbers. RET signals provide HSCs with critical Bcl2 and Bcl211 surviving cues, downstream of p38/MAP kinase and CREB activation. Accordingly, enforced expression of RET down-stream targets, Bcl2 or Bcl211, is sufficient to restore the activity of Ret null progenitors in vivo. Remarkably, activation of RET improves HSC survival or maintenance and in vivo transplantation efficiency, thus opening new horizons to the usage of RET agonist in HSC expansion and transplantation protocols. Additionally, the present disclosure describes a kit comprising RET agonist molecules, to be used in HSC expansion protocols and transplantation therapy.

Abstract: This invention provides processes for creating and stabilizing extracts of platelets possessing improved properties for tissue engineering and cell culture applications relative to other methods, that can be made without the use of freeze lysis, the resulting compositions, and methods for using them.

Abstract: Methods and compositions are disclosed for an intra-articular injection for the treatment of osteoarthritis. The methods and compositions comprising combinations of hyaluronic acid and a bone morphogenetic protein, like rhGDF-5, can be useful for any synovial joint, including the knee, shoulder, hip, ankle, hands, spinal facet, or temporomandibular joint, both for the relief of pain and for slowing disease progression.

Abstract: A combination therapy comprising administration of a Smac mimetic and GM-CSF.

Abstract: The application provides new compositions and methods for stimulating the production of natural killer (NK) cells in a subject. NK cells can be selectively expanded with a combination of stimulating ligands. Methods and compositions for the administration of stimulatory ligands modified to self-insert into tumor cells, thereby stimulating an increase in the number of NK cells in proximity to a tumor, are also described.

Abstract: The present invention is related to the use of the angiotensin-(1-9) peptide or peptides derived therefrom, which are biological or chemical analogues, for preparing medicaments useful for preventing, reverting, inhibiting and/or reducing hypertension and/or inducing vasodilation. Furthermore, this invention also comprises a vector overexpressing the homologous angiotensin-II converting enzyme (ACE2) for elevating the concentration in the blood and/or tissues of the angiotensin-(1-9) peptide. This vector may be adenovirus, retrovirus, lentivirus or adeno-associated virus containing the gene encoding for ACE2.